
Please try another search
C4X Discovery Holdings PLC is a drug discovery company. The Company has a portfolio ranging from early-stage novel target opportunities to late-stage drug discovery programs ready for out-licensing to partners. Its Taxonomy3 technology is used to analyze complex genetic datasets to identify and characterize novel drug target candidates. Its Conformetrix technology platform allows the 3D-shapes of free ligands to measure from experimental data. Its pipeline includes Oral NRF2 activator, Oral MALT1 inhibitor, Oral α4β7 integrin inhibitor and Oral Orexin-1 Antagonist (C4X 3256/INDV-2000). It has developed activators of the NRF2 pathway for the treatment of a variety of inflammatory diseases including Inflammatory Bowel Disease (IBD), Sickle Cell Disease (SCD), Pulmonary Arterial Hypertension (PAH) and Chronic Obstructive Pulmonary Disorder (COPD). MALT1 is a hematological cancer target for Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL).
Name | Age | Since | Title |
---|---|---|---|
Eva-Lotta Coulter | 62 | 2018 | Independent Non-Executive Chairman of the Board |
Mario Polywca | - | 2021 | Non-Executive Director |
Natalie Louise Walter | - | 2018 | Independent Non-Executive Director |
Mario Polywka | 59 | 2021 | Independent Non-Executive Director |
Alexander James Stevenson | 50 | 2014 | Independent Non-Executive Director |
Clive James Dix | 67 | 2014 | CEO & Executive Director |
Bhavna Hunjan | 36 | 2017 | Chief Business Officer & Executive Director |
Bradley Richard Hoy | 59 | 2016 | CFO, Secretary & Executive Director |
Simon Nicolas Reade Harford | 61 | 2021 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review